Remission in Adults With Mild-to-moderate Asthma in Thailand

Sponsor
Thammasat University
Study ID
NCT07351916
Status
Recruiting
Apply to this trial

Conditions

  • Asthma
  • Asthma Control Level
  • Mild-to-moderate Asthma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Global Initiative for Asthma (GINA) and Asthma Control Test (ACT) questionnaires — OTHER
    GINA and ACT are questionnaires used to assess the level of asthma control.
  • Spirometry — OTHER
    Spirometry is a tool used to assess pulmonary function.
  • Fractional exhaled nitric oxide (FeNO) test — OTHER
    FeNO is a tool used to assess eosinophilic airway inflammation and asthma remission.
  • Blood eosinophil count (BEC) — OTHER
    BEC is a tool used to assess eosinophilic inflammation and asthma remission.

Study Details

The goal of this observational study is to determine the prevalence of remission among adults with mild-to-moderate asthma, as well as the factors associated with remission in Thailand. The main question the study aims to answer is: What is the prevalence of remission among adults with severe asthma in Thailand? Participants will complete a questionnaire on asthma symptoms and undergo pulmonary function testing and a blood test once.

Key Dates

First listed
Jan 20, 2026
Start date
Feb 1, 2026
Status verified
Apr 2026
Primary completion
Oct 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
289 participants (estimated)

Arms

  • Arm: Mild-to-moderate asthma
    Patients aged 18 years or older with mild-to-moderate asthma. Mild asthma refers to asthma patients who experience symptoms \<3 times per week, have preserved lung function (FEV₁ or PEF \>80% of predicted), and whose symptoms can be adequately controlled with low-dose inhaled corticosteroids (low-dose ICS) alone, without the need for long-acting bronchodilators or other controller medications. Moderate asthma refers to asthma patients who have symptoms \>4-5 days per week or experience nocturnal asthma symptoms \>1 per week, and who require treatment with medium-dose inhaled corticosteroids (medium-dose ICS) or low-dose ICS in combination with a long-acting β₂-agonist (low-dose ICS/LABA) to achieve symptom control and prevent exacerbations.

Primary Outcome Measure

Prevalence rate of mild-to-moderate asthma remission [ Time Frame: An average of 1 year ]

Central Contacts

Find similar trials

Nationwide
Asthma trialsPulmonology trialsLung disease trials

Related Studies